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Abstract: The Wnt signalling pathway plays an important role in cell proliferation, differentiation,
and fate decisions in embryonic development and the maintenance of adult tissues. The twelve
armadillo (ARM) repeat-containing protein β-catenin acts as the signal transducer in this pathway.
Here, we investigated the interaction between β-catenin and the intrinsically disordered transcription
factor TCF7L2, comprising a very long nanomolar-affinity interface of approximately 4800 Å2 that
spans ten of the twelve ARM repeats of β-catenin. First, a fluorescence reporter system for the
interaction was engineered and used to determine the kinetic rate constants for the association
and dissociation. The association kinetics of TCF7L2 and β-catenin were monophasic and rapid
(7.3 ± 0.1 × 107 M−1·s−1), whereas dissociation was biphasic and slow (5.7 ± 0.4 × 10−4 s−1,
15.2 ± 2.8 × 10−4 s−1). This reporter system was then combined with site-directed mutagenesis to
investigate the striking variability in the conformation adopted by TCF7L2 in the three different
crystal structures of the TCF7L2–β-catenin complex. We found that the mutation had very little effect
on the association kinetics, indicating that most interactions form after the rate-limiting barrier for
association. Mutations of the N- and C-terminal subdomains of TCF7L2 that adopt relatively fixed
conformations in the crystal structures had large effects on the dissociation kinetics, whereas the
mutation of the labile sub-domain connecting them had negligible effect. These results point to a
two-site avidity mechanism of binding with the linker region forming a “fuzzy” complex involving
transient contacts that are not site-specific. Strikingly, the two mutations in the N-terminal subdomain
that had the largest effects on the dissociation kinetics showed two additional phases, indicating
partial flux through an alternative dissociation pathway that is inaccessible to the wild type. The
results presented here provide insights into the kinetics of the molecular recognition of a long
intrinsically disordered region with an elongated repeat-protein surface, a process found to involve
parallel routes with sequential steps in each.
Keywords: repeat protein; tandem-repeat protein; intrinsic disorder; intrinsically disordered protein;
fuzzy complex; protein-protein interactions; protein folding; armadillo repeat; beta-catenin; TCF
1. Introduction
β-catenin fulfils two important functions in vivo, the first of which is as the signal
transducer in the canonical Wnt signalling pathway [1]. Upon Wnt stimulation, β-catenin
translocates to the nucleus, where it binds the T-cell factor/lymphoid enhancer-binding
factor (TCF/LEF) family of transcription factors [2] and associates with a number of other
proteins to form the Wnt enhanceosome [3], thus leading to transcription initiation and elon-
gation, as well as histone and chromatin modification [4,5], resulting in the transcription
of genes that are of developmental importance and those involved in tissue homeostasis.
In the absence of a Wnt signal, cytosolic β-catenin is continuously synthesised and then
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sequestered and targeted for proteasomal degradation by a multi-protein complex called
the β-catenin destruction complex (BDC) that forms biological condensates [6]. The BDC
comprises five different proteins: two structural proteins (axin and adenomatous polypo-
sis coli (APC)), two kinases (glycogen synthase kinase 3β (GSK3β) and casein kinase 1α
(CK1α)), and protein phosphatase 2A (PP2A). In the BDC, β-catenin is hyperphosphory-
lated at its N-terminal disordered region by the combined action of GSK3β and CK1α [7],
thus allowing it to be recognised and ubiquitinated by the E3 ubiquitin ligase β-TrCP [8]
and subsequently degraded by the proteasome. The second function of β-catenin is as an
adaptor that mediates cell–cell adhesion at adherens junctions, where β-catenin binds to
the intracellular domain of the cadherin family of proteins [1,9–11]. The deregulation of
Wnt signalling has been implicated in numerous types of cancer [12], including colorectal
and hepatocellular cancers. Additionally, the disruption of β-catenin binding at adherens
junctions is also cancer-promoting [13]. In addition to being inherently pro-metastatic
through the weakening of cell–cell adhesion [14], adherens junction-associated β-catenin
constitutes a significant cellular pool of β-catenin [15], the release of which can result in its
nuclear accumulation and unregulated gene activation [16].
β-catenin has a ~530-residue central domain of 12 armadillo (ARM) tandem repeats
flanked at each end by ~100-residue disordered regions [17,18]. The twelve imperfect
ARM repeats linearly stack to form a right-handed superhelix of helices. The third helix of
each ARM repeat lines the groove formed by the superhelix and is enriched in positively
charged residues [17] Thus, the repeat array creates an elongated surface for β-catenin’s
negatively-charged, intrinsically-disordered binding partners, APC, E-cadherin and the
TCF/LEF family of transcription factors that wrap around it [19–23], (Figure 1).
Figure 1. Interactions of β-catenin and its partner proteins. Schematic showing the superposition of
the crystal structures of β-catenin (cyan) in complex with its seven binding partners (various colours),
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as visualised in UCSF Chimera [24]: Xenopus TCF7L1 (PDB ID 1G3J, [20] human Tcf4) (2GL7, [25] axin
(1QZ7, [26])), APC third repeat (1TH1, [23]), ICAT (1LUJ, [27]), the cytoplasmic domain of E-cadherin
(3IFQ, [28]), and human Lef-1 (3OUW, [29]). Disordered regions that are not visible in the crystal
structures are denoted by a dashed line. All partner proteins, except for axin, bind in an antiparallel
configuration relative to β-catenin. The consensus binding motif of β-catenin binding partners is
DxΦΦxΩx2–7E—where Φ indicates a hydrophobic residue and Ω indicates an aromatic residue these
residues are shown.
The target genes for the canonical Wnt pathway have a conserved sequence that binds
to members of the TCF/LEF family of transcription factors, of which transcription factor
7-like 2 (TCF7L2, also known as Tcf4) has been the most widely studied to date [30,31].
TCF7L2 mutations are implicated in many types of cancers [32] and have been shown to pro-
mote the migration and invasion of human colorectal cancer cells [33–35]. Single nucleotide
polymorphisms within the TCF7L2 gene are also a genetic biomarker for an increased risk
of both type 2 and gestational diabetes [36,37]. TCF7L2 is like many mammalian transcrip-
tion factors in having an intrinsically disordered region (IDR). The absence of fixed tertiary
structure is thought to give proteins conformational plasticity and enable them to bind to
a number of different macromolecules in response to physiological needs [38–44]. Given
their capacity to adjust to any given binding partner, the range of structures adopted by
IDRs upon complex formation is unsurprising. Broadly, these can be divided into static
complexes [45], where the IDR is ordered (and visible in X-ray crystal structures), and
dynamic or “fuzzy” complexes, where the IDR retains a significant proportion (sometimes
all) of its disorder in the complex [46–48]. IDP binding mechanisms are equally varied,
and they have been grouped into four distinct classes: simple two-state binding, avidity,
allovalency, and fuzzy binding [49]. Even in the more simple case of two-state binding,
association can involve conformational selection or folding upon binding [50–54].
Intriguingly, there are three crystal structures of TCF7L2 in complex with the ARM
repeat domain of β-catenin, with TCF7L2 adopting different conformations and making
different β-catenin contacts in each (Figure 2) [20,22,25,55], though the Poy structure
has poor refinement. In addition, there are significant portions of missing residues, and
different regions are resolved in the different structures, suggesting that TCF7L2 is highly
dynamic in complex with β-catenin. Similar behaviour has been observed in the crystal
structures of other β-catenin complexes, providing tantalising hints to the underlying
mechanisms of recognition [10,21,23,26–28,56]. Most recently, a single-molecule study by
Hofmann and co-workers on the interaction between β-catenin and E-cadherin revealed
a rugged energy landscape of E-cadherin with many shallow minima, a fuzzy complex,
and a mechanism of intrachain diffusion of E-cadherin on β-catenin [57]. Here, we used
site-directed mutagenesis and kinetic analysis to explore the significance of this plasticity
in the β-catenin–TCF7L2 complex and to define the mechanism of association between the
two proteins.
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Figure 2. Schematics showing the crystal structures of the β-catenin–TCF7L2 complex. (A–C) show the structures of TCF7L2
(red) in complex with β-catenin (cyan) obtained by Poy et al. [22], Graham et al. [57], and Sampietro et al. [55], respectively.
Structure (C) also has a peptide from the bound protein BCL9 (purple). (D–F) are schematics highlighting the different
conformations of TCF7L2 between the three structures and indicating the positioning of the key contact residues within each
structure. Images (A–C) were created using UCSF Chimera [24] from PDB 1JPW [22], 1JDH [55], and 2GL7 [25], respectively.
2. Materials and Methods
2.1. Molecular Biology and Protein Expression and Purification
Mutations in the β-catenin binding fragment of TCF7L2 (1–54 amino acids) were
introduced by site directed mutagenesis. The plasmid encoding the ARM repeat domain of
human β-catenin (residues 134–671) was a kind gift from Prof. W.I. Weis. All proteins were
expressed in E. coli C41 cells [58]. Transformed cells were grown in 2TY with appropriate
antibiotic until an OD600 of 0.6 at 37 ◦C was reached. Then the temperature was lowered
to 25 ◦C, and protein expression were induced with 0.2 mM IPTG. After a further 18 h,
the cells were harvested at 5000 g for 7 min at 4 ◦C. The cells were resuspended in 50 mM
Tris-HCl buffer pH 7.5, 150 mM NaCl, and 1 mM DTT containing protease inhibitors and
lysed using an Emusiflex C5 (Avestin, Ottawa, ON, Canada) at 10,000 psi. The lysed cells
were centrifuged at 35,000× g for 35 min at 4 ◦C.
The GST-tagged β-catenin supernatant was incubated with glutathione-Sepharose 4B
(Cytiva, Little Chalfont, Bucks, UK) and washed to remove unbound proteins. The GST tag
was cleaved from the target protein on resin using thrombin, and the protein was eluted.
β-catenin was further purified using a Mono-Q column (Cytiva, Little Chalfont, Bucks, UK)
equilibrated in a 50 mM Tris-HCl buffer pH 8.9, 50 mM NaCl, and 1 mM DTT. β-catenin
was eluted with a linear NaCl gradient to 1 M NaCl. Fractions containing greater than 95%
β-catenin were pooled snap-frozen and lyophilised and stored at −80 ◦C.
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The His-tagged TCF7L2 constructs were affinity-purified using Ni-NTA agarose (Qi-
agen, Manchester, UK), and the tagged constructs were cleaved from the protein using
thrombin. The TCF7L2 was further purified on a HiLoad 26/600 Superdex 75 pg (Cytiva,
Little Chalfont, Bucks, UK) equilibrated in PBS (phosphate buffer saline) containing 1 mM
DTT. The fractions corresponding to A215 peaks were analysed by SDS-PAGE, and the
fractions containing TCF7L2 at greater than >95% purity were flash-frozen with liquid
nitrogen and stored at −80 ◦C until use.
The identities of all proteins were confirmed by MALDI mass spectrometry performed
by Dr. Len Packman. The protein concentration of β-catenin was calculated from its extinc-
tion coefficient obtained using ProtParam [59] at 280 nm, and TCF7L2 protein concentration
was measured using the Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific, Waltham,
MA, USA) or by ion-exchange-ninhydrin analysis performed by Dr. Peter Sharratt (PNAC
Facility, Department of Biochemistry, University of Cambridge, Cambridge, UK).
2.2. Fluorescent Labelling of TCF7L2
The maleimide functional group reacts with sulfhydryl groups via nucleophilic conju-
gation addition and was used to label the proteins at a cysteine residue. A 500 µL aliquot
of a TCF7L2 (1–54) construct containing a cysteine residue was buffer-exchanged into PBS.
A stock solution of 20 mM fluorescein maleimide in 100% DMSO was added at a 5-times
molar excess and incubated at 37 ◦C in the dark for 1 h. Excess fluorescein maleimide
was removed by the method of Vivès and Lebleu, [60]. In brief, a 10× volume of acetone,
pre-chilled to −20 ◦C, was added to the labelling reaction mixture, mixed by vortex, and
incubated at −20 ◦C for 30 min. Fluorescein and its derivatives are very soluble in acetone,
whereas peptides and proteins are insoluble. The addition of acetone to 90+% caused the
protein to precipitate out of solution, while the unreacted fluorescein maleimide remained
in solution. The reaction mixture was centrifuged at 15,000× g at 4 ◦C for 10 min to collect
the precipitated and labelled protein, and then the supernatant was removed and the pellet
was resuspended in PBS. This acetone wash process was repeated twice more, but the
precipitated protein pellet was not resuspended on the final wash. The final precipitated
protein pellet was left at room temperature and open to the air for 16 h to ensure that any
residual acetone had evaporated, after which the desiccated and labelled TCF7L2 was
stored at 4 ◦C for up to 5 days without a loss of activity.
2.3. Isothermal Titration Calorimetry (ITC)
ITC measurements were performed using the VP-ITC calorimeter (Malvern Panana-
lytical, Malvern, UK). Both β-catenin and TCF7L2 constructs were stored as lyophilised
powders after labelling. To ensure matched buffers, lyophilised β-catenin was resuspended
in ultra-pure water, the buffer was exchanged into PBS, 1 mM DTT, and the TCF7L2 was
resuspended in the same buffer. Unlabelled TCF7L2 was washed with acetone three times,
as previously described, to produce a lyophilised pellet. β-catenin was used at a concen-
tration of 2–4 µM in the cell, and TCF7L2 was used at 6–100-fold higher concentration in
the syringe (18–40 µM). Titrations of TCF7L2 into the buffer and the buffer into β-catenin
were performed as controls. All experiments were performed at 30 ◦C. Data were fitted the
Origin software package supplied with the instrument using the one-site binding equation.
Data is shown in Supplementary Materials.
2.4. Kinetic Experiments
Stopped-flow spectroscopy was performed using an SX-19 Stopped flow fluorimeter
(Applied Photophysics, Surrey, UK) in fluorescence mode. The excitation and emission
wavelengths were set to 495 and 519 nm, respectively, and a 515 nm long-pass filter
was used to improve the signal to noise ratio. All proteins were prepared in a fresh
PBS buffer, 1 mM DTT, and the experiments were performed at 15 ◦C. The β-catenin
concentrations were at least ten times higher than that of the TCF7L2 to ensure pseudo first-
order conditions; a fixed concentration of a fluorescent-labelled TCF7L2 (10 nM) construct
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was rapidly mixed in a 1:1 volume ratio, with varying concentrations of unlabelled β-
catenin (between 100 nM and 1000 nM), and the change in fluorescence intensity was
recorded. For dissociation experiments, a complex of labelled TCF7L2 and β-catenin was
pre-formed by mixing the two proteins in a 1:1 molar ratio (200 nM) and incubating them
at 15 ◦C for 1 h in the dark to reach equilibrium. The pre-formed complex was then mixed
in a 1:1 volume ratio with 50-times molar excess of unlabelled wild-type TCF7L2 (10 µM),
and the change in fluorescence intensity was measured. A minimum of three traces was
collected and averaged. The average was plotted using GraphPad Prism 6 (GraphPad
Software, Ltd., San Diego, CA, USA) and fitted to either a single exponential phase or the
sum of two exponential phases.
For the association experiments, the observed rate constants, kobs, were plotted against
the concentration of β-catenin and kon calculated from the linear fit:
kobs = kon[βcatenin] + c (1)
For the slow dissociation kinetics, fluorescence spectroscopy was performed using
a LS55 Luminescence Spectrometer (PerkinElmer, Waltham, MA, USA) using a cell of
pathlength 10 mm. The excitation and emission wavelengths were set to 495 and 519 nm,
respectively; both the excitation and emission shutter width were 5 nm; and the photo-
multiplier tube was set at 650 V. All proteins were prepared in a fresh 1× PBS buffer with
1 mM DTT, and the experiments were performed at 15 ◦C, except when otherwise stated.
A complex of labelled TCF7L2 and β-catenin was pre-formed by mixing to two proteins in
a 1:1 molar ratio and incubating them at 15 ◦C for 1 h in the dark to reach equilibrium. The
pre-formed complex was then mixed in a 1:1 ratio with 50-times molar excess unlabelled
WT TCF7L2, and the change in fluorescence intensity was measured. The traces were fitted
as described above.
3. Results
3.1. The Association of TCF7L2 and β-Catenin Is Monophasic, and the Dissociation of the Complex
Is Biphasic
In order to study the kinetics of TCF7L2–β-catenin complex formation and dissociation,
we used a recombinant fragment of TCF7L2 comprising the N-terminal 54-residue β-
catenin binding domain. We made a conservative serine to cysteine mutation in the
wild-type TCF7L2 (1–54) to allow us to label the protein at a unique site. The wild-type
TCF7L2 (1–54) construct contains eight serine residues, excluding the one left behind
as a result of removing the purification tag with thrombin. The crystal structures were
inspected to find a position where the addition of a bulky, hydrophobic dye molecule
would not have a significant steric effect on binding but would be able to report on
complex formation. A contact map analysis revealed that only one serine residue, S31,
formed no contacts to β-catenin in any of the crystal structures, indicating that it is in a
sterically unhindered position. Consequently, S31 was mutated to a cysteine for labelling
with fluorescein maleimide at this position. The TCF7L2 (1–54) S31C construct is hereafter
referred to as “WT” and is used as a pseudo-wild type with which all other TCF7L2 mutants
are compared. In order to determine whether the S31C mutation and its subsequent
labelling with fluorescein maleimide had a significant effect on TCF7L2 binding to β-
catenin, equilibrium binding experiments were performed using ITC. Previous studies
have used ELISA [61] and ITC [29] to determine the binding affinities for β-catenin and
similar TCF7L2 fragments. The values they obtained were 15 ± 6 nM and 16 ± 3 nM for
TCF7L2 (1-53) and TCF7L2 (1-57), respectively. The results of the ITC experiments showed
that there was no significant difference between TCF7L2 (1–54), WT, fluorescein-labelled
WT, and the previous literature values (Table S1 and Figure S1).
Association kinetics were monitored by the change in fluorescence intensity of the
conjugated fluorescein moiety in a stopped-flow fluorimeter. Dissociation kinetics were
monitored using either a stopped-flow fluorimeter or a fluorescence spectrometer, depend-
ing on the timescale of the reaction. Association kinetics were initiated by rapid mixing in
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the stopped-flow of solutions containing a fixed concentration of fluorescein-labelled WT,
as well as varying concentrations of β-catenin, in order to produce a pseudo-first-order
regime. All of the association traces showed a mono-exponential decrease in fluorescence
with time, indicating a single association event (Figure 3). Additionally, the observed
association rate (kobs) linearly increased with increasing β-catenin concentration, thus con-
firming that the reaction is bimolecular. The association rate constant, kon, calculated from
the pseudo-first-order plot, was 7.33 ± 0.14 × 107 M−1·s−1.
Figure 3. Stopped-flow fluorescence measurement of the association kinetics of TCF7L2 and β-catenin. (A) Time-dependent
change in fluorescence upon the mixing of 10 nM fluorescent-labelled WT TCF7L2 (1–54) and 900 nM β-catenin. The data
were fitted to a single-exponential function, and the residuals are shown below the main plot. (B) The observed rate constant
was plotted as a function of the concentration of β-catenin, from which the association rate constant, kon, was calculated.
The errors bars in (B) are the standard deviations of the fits. Experiments were performed in PBS buffer, 1 mM DTT at 15 ◦C.
Dissociation kinetics were monitored by first forming a 1:1 complex of β-catenin and
fluorescent-labelled WT TCF7L2. The complex was dissociated by mixing with excess
unlabelled TCF7L2 (1–54). Dissociation traces showed a biphasic increase in fluores-
cence intensity, demonstrating that, unlike association, dissociation is a two-step pro-
cess (Figure 4). The traces did not reach a plateau when monitored by stopped flow
(Figure 4A), and a fluorimeter was consequently used instead (Figure 4B). The data
were fitted to the sum of two exponential phases, comprising a major slow phase with
koff,major = 5.73 ± 0.40 × 10−4 s−1 (relative amplitude of 77 ± 3%) and a minor fast phase
with koff,minor = 1.52 ± 0.28 × 10−3 s−1 (relative amplitude of 23 ± 3%). The dissociation
kinetics were independent of β-catenin concentration.
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Figure 4. Stopped-flow and time-dependent fluorescence spectroscopy measurements of the dissociation of the WT TCF7L2–
β-catenin complex. First, a 200 nM fluorescent-labelled WT TCF7L2–β-catenin complex was mixed in with 50-times
molar excess of unlabelled WT TCF7L2 (1–54), and the reaction was monitored by (A) stopped-flow fluorescence and
(B) fluorescence. The traces were fitted to a single exponential phase and to the sum of two exponential phases, and the
corresponding residuals are plotted below the main plot. Experiments were performed in a PBS buffer, 1 mM DTT at 15 ◦C.
3.2. Alanine Scanning of TCF7L2 Reveals Three Distinct Interface Regions
To investigate the contribution of individual residues to the kinetics of the TCF7L2–
β-catenin interaction, an alanine scan of TCF7L2 was performed. Residues spanning the
length of the β-catenin binding interface were mutated to alanine. The association traces of
all of the mutants showed a single-exponential decrease in fluorescence intensity, similar
to that of WT, and none had a significant effect on the association rate constant (Table 1).
Several mutants had a very large effect on the dissociation kinetics (Table 1). For I19A, the
dissociation kinetics were sufficiently fast to be measurable on the stopped-flow instrument
and the fluorimeter. For I19A, F21A, L41A, and V44A, the dissociation kinetics were too
fast for the fluorimeter, and the stopped flow was used instead. For all mutants except
I19A and F21A, which are discussed in more detail below, the dissociation traces were
biphasic with a major slow phase of 70–90% and a minor fast phase of 10–30%, similar to
those of WT.
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Table 1. Association and dissociation kinetics for the interaction of alanine mutants of TCF7L2 with β-catenin. All mutations
were constructed in the S31C variant (denoted as WT) and were labelled with fluorescein at this position. Association
kinetics were measured on a stopped-flow fluorimeter, and dissociation kinetics were measured on a fluorimeter. * The
exceptions are I19A, F21A, L41A, and V44A, for which the data listed for association and dissociation kinetics were obtained











WT 7.33 ± 0.14 5.73 ± 0.40 1.52 ± 0.28 23 ± 3
L12A 7.19 ± 0.13 9.77 ± 0.75 2.64 ± 0.20 19 ± 12
N15A 6.25 ± 0.23 4.42 ± 0.15 3.65 ± 0.83 18 ± 2
E17A 6.30 ± 0.42 89.1 ± 2.9 28.3 ± 1.9 28 ± 4
I19A * 7.04 ± 0.52 110 ± 0.5 207 ± 10 15 ± 0.1
F21A * 4.82 ± 0.17 258 ± 2 423 ± 15 20 ± 0.1
D23A 5.31 ± 0.25 3.00 ± 0.16 2.39 ± 0.70 15 ± 1
E24A 6.05 ± 0.12 5.03 ± 0.40 1.53 ± 0.21 26 ± 1
E26A 5.59 ± 0.22 4.74 ± 0.30 1.66 ± 0.16 24 ± 4
E28A 5.84 ± 0.35 4.96 ± 0.35 1.16 ± 0.28 23 ± 5
E29A 5.73 ± 0.43 8.97 ± 0.44 2.45 ± 0.21 18 ± 2
E38A 6.20 ± 0.19 5.39 ± 0.50 2.61 ± 0.28 30 ± 1
L41A * 5.95 ± 0.24 993 ± 17 616 ± 111 11 ± 0.4
V44A * 5.05 ± 0.46 742 ± 8 498 ± 70 11 ± 0.4
K45A 10.31 ± 0.19 21.9 ± 0.4 15.0 ± 1.3 19 ± 1
L48A 5.67 ± 0.60 13.2 ± 0.1 4.24 ± 0.13 17 ± 0.6
E24A E29A 6.13 ± 0.34 4.25 ± 0.29 1.73 ± 0.14 18 ± 4
D23A E24A E26A E28A E29A (5X) 4.26 ± 0.17 2.95 ± 0.23 2.34 ± 0.33 15 ± 2
From these data, we were able to divide TCF7L2 into three distinct regions, which we
refer to as the N-terminal binding region (residues 12–22), the variable region (residues
23–39), and the C-terminal binding region (residues 40–50) (Figure 5). Mutations in the N-
and C-terminal binding regions had a much larger effect on the TCF7L2–β-catenin kinetics
than mutations within the variable region, and a similar trend was previously observed for
the equilibrium binding [61,62]. The contributions of the three regions to binding appeared
to mirror their conformational properties in crystallo in that the N- and C-terminal regions,
which contribute most to the binding affinity, adopted a relatively ‘fixed’ conformation
that was similar in all three crystal structures, whereas the variable region was more
flexible or ‘pliable,’ adopted different conformations in the three structures, and made little
contribution to binding affinity.
Figure 5. Schematic showing the three interface regions (N, variable (V), and C) of TCF7L2. The schematics show
the conformational preferences of TCF7L2 (red) in complex with β-catenin (cyan) in the different crystal structures.
(A–C) are based on the crystal structures of Poy et al. (PDB 1JPW, [22]), Graham et al. (1JDH, [20]), and Sampietro et al.
(2GL7, [25]), respectively. The N-terminal binding domain (N) and the C-terminal binding domain (C) each adopt very
similar conformations in all three structures, but the variable region (V) had a different conformation in each structure.
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3.3. Multi-Site Mutations in the Variable Region of TCF7L2 Do Not Perturb the Kinetics
Next, we sought to further explore the role of the variable region. The Sampietro
and Poy structures [22,25] both showed Glu24 of TCF7L2 interacting with Lys312 of β-
catenin (Figure 5A,C). In the Graham structure [20], it was Glu29 that interacted with
Lys312; this difference appeared to be due to residues 21–32 of TCF7L2 forming an α-helix
rather than an extended conformation, forcing Glu24 to point away from the surface of
β-catenin and positioning Glu29 in the equivalent position where it could interact with
Lys312 (Figure 5B). Other studies of β-catenin complexes have identified Lys312 and
Lys435 as key interaction residues (often referred to as the “lysine buttons” or “charged
buttons”), and so it seems strange that there should have been such variation in the TCF7L2
structure at this critical interface with β-catenin [20,29,63,64]. In the Graham structure,
the entire variable region of TCF7L2 (residue 23–39) was resolved, whereas in the other
two structures, a significant number of residues were disordered and not visible (residues
27–39 in the Poy structure and residues 29–37 in the Sampietro structure). Additionally, the
C-terminal α-helix (residues 41–49), which was present in all three structures, had an extra
turn in the Graham structure (residues 37–40). These more extensive helical stretches of the
Graham structure had the effect of pulling the variable region across the β-catenin surface.
We noticed that there were a further three Glutamate residues close to Glu24 and Glu29
that could potentially interact with Lys312 of β-catenin (Glu23, Glu26, and Glu28), and
we postulated that conformations may be populated other than those that are observed
in crystallo. By altering the location and length of the N-terminal α-helix of Graham’s
structure, the register would be altered and Glu26 or Glu28 could be presented to the
lysine button. To investigate this possibility, two additional alanine variants, the double
mutant E24A E29A and the quintuple mutant D23A E24A E26A E28A E29A (referred
to subsequently 5X), were made. We were surprised to find, given the anticipated key
interaction of Glutamate with the lysine button, that neither the double mutant nor the
quintuple mutant had a significant effect on the kinetics.
3.4. TCF7L2 Mutants I19A and L21A Display More Complex Dissociation Kinetics
The dissociation kinetics of the TCF7L2 I19A mutant occurred over a faster timescale
than that of WT and could be measured on both the stopped-flow instrument and the
fluorimeter (Figure 6). On the stopped flow, the kinetics traces were adequately captured
by a biphasic equation with a minor fast phase of 15% of the total amplitude and a major
slow phase of 85%, in line with the other mutants. A biphasic equation was also used to fit
the kinetic traces obtained with the fluorimeter, with a major fast phase of 82% amplitude
and a minor slow phase of 18% amplitude. The slower phase obtained from stopped flow
and the faster phase obtained from the fluorimeter had similar rate constants (11.0 × 10−3
and 16.5 × 10−3 s−1, respectively), suggesting that the dissociation of I19A comprises a
least three phases in total.
We next attempted to fit the dissociation kinetics of TCF7L2 I19A to a three-phase
exponential function, and the obtained rate constants and relative amplitudes are
listed in Table 2. Using the fluorimeter, the major phase (75%) had a rate constant of
15.0 ± 0.8 × 10−3 s−1, and there was a minor (15%) slow phase of 2.7 ± 0.1 × 10−3 s−1
and a minor (10%) fast phase of 88 ± 19 × 10−3 s−1. Using the stopped flow, the ma-
jor phase (79%) was the slowest phase, with a rate constant of 9.1 ± 0.2 × 10−3 s−1, and
there were two faster minor phases with rate constants of 65.2 ± 7.3 × 10−3 (15%) and
535 ± 70 × 10−3 s−1 (16%), as well as a minor middle phase. These results indicated that
there were at least three and likely four phases in the dissociation of I19A from β-catenin.
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Figure 6. Dissociation kinetics of TCF7L2 I19A. (A,B) are representative dissociation traces for I19A obtained using the
fluorimeter and the stopped-flow instrument, respectively. The data were fitted to one-, two-, and three-phase exponential
functions, and the residuals are also shown (red, green, and blue, respectively). Experiments were performed in a PBS
buffer, 1 mM DTT at 15 ◦C.
















Fluorimeter - - 87.6 ± 18.8 10 ± 0.5 15.0 ± 0.8 75 ± 4.5 2.66 ± 0.06 15 ± 4
Stopped flow 535 ± 70 6 ± 0.5 65.2 ± 7.3 15 ± 0.8 9.1 ± 0.2 79 ± 0.3 - -
Likewise, for the F21A mutant, the dissociation kinetics measured by stopped-flow
were originally fitted to the sum of two exponential phases with a major slow phase (80%)
of 25.8 ± 0.2 × 10−3 s−1 and a minor fast phase (20%) of 423 ± 15 × 10−3 s−1. However,
when these data were fitted to the sum of three exponential phases, there was a major slow
phase (66%) of 20.3 ± 0.2 × 10−3 s−1, a second faster phase (22%) of 91.8 ± 5.9 × 10−3 s−1,
and a third and fastest phase (12%) of 794 ± 68 × 10−3 s−1. This behaviour was similar to
the dissociation kinetics observed for I19A by stopped flow.
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In contrast to these two fast-dissociating N-terminal mutants, the kinetics of the two
fast-dissociating C-terminal mutants L41A and V44A were biphasic like the WT, and there
was no evidence of additional phases.
3.5. The Variable Region of TCF7L2 Is Very Sensitive to Ionic Strength
One of the major contributors to binding energy are electrostatic interactions, and their
contribution can be investigated by varying the ionic strength of a buffer and measuring
the changes in the association and dissociation rate constants. The magnitude of these
variations can be assessed from the slopes of the plots of log(kon) and log(koff) versus
log([NaCl]), referred to as ΓonNaCl and Γ
o f f
NaCl , respectively [65–67]. A negative value for Γ
on
NaCl
and a positive value for Γo f fNaCl indicate that the complex is destabilised by increasing ionic












We used this method to test the interaction of β-catenin with both the WT TCF7L2 and
the 5X variant, as we thought that the removal of five negatively charged residues might
produce a significant change in any electrostatic interactions at the binding interface. We
found for both WT and 5X that the association rate decreased with increasing ionic strength
and the dissociation rate increased with increasing ionic strength (Figure 7 and Table 3).
However, the ionic strength dependence of the WT interaction was greater than that of the
5X mutant, and the 5X mutation had a much larger effect on the ionic strength dependence
of dissociation (Γo f f majorNaCl and Γ
o f f minor
NaCl ) than on the salt dependence of association.
Figure 7. The effect of varying NaCl concentration on the kinetics of the interaction between β-catenin and the WT TCF7L2
and 5X variant. The effects of increasing NaCl concentration on the rate constant for association (A) and the rate constants
for the two dissociation phases (B).
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WT −1.72 ± 0.08 1.50 ± 0.13 1.89 ± 0.20
5X −1.33 ± 0.07 0.61 ± 0.06 0.70 ± 0.12
4. Discussion
Our analysis of the kinetics of the β-catenin–TCF7L2 interaction was dissected by
site-directed mutagenesis and uncovered a complex molecular recognition mechanism. We
found that there are two key interface regions of TCF7L2—an N-terminal binding region
(residues 12–22) and a C-terminal binding region (residues 40–48)—that significantly
contribute to the binding to β-catenin, and these are the regions that are the most similar
between the different crystal structures. The single-exponential nature of the association
kinetics makes it impossible to distinguish which section of this extended interface binds
first, but it does suggest that any intermediates are of high energy, thus indicating that that
binding is highly co-operative. The trends observed in the alanine scan were consistent
with an avidity mechanism of interaction [49] between β-catenin and TCF7L2; the N- and
C-terminal binding regions are connected by a flexible linker, each region binding its own
cognate site on β-catenin, and once one site is bound, the other region is held close in space
to its corresponding binding site.
The central conformationally ‘variable’ region of TCF7L2 (residues 22–40), in which
mutation had no effect on either the association or dissociation kinetics, could be regarded
as a structurally malleable or “fuzzy” interaction generated by multiple rapidly exchang-
ing high-entropy contacts, eventually leading to a low entropy state [68,69]. This type
of fuzzy interaction, which lacks site-specific interactions, was also recently seen for an-
other binding partner of β-catenin, namely the 15-amino acid repeat region of APC [70].
This fuzziness of the binding of different partners involved in balancing the competing
pathways of transcription and degradation may allow for faster responses between the
different pathways.
For the WT and alanine mutants in the C-terminal region of TCF7L2, the dissociation
appeared to be biphasic. This behaviour could be explained as arising from sequential
dissociation (Figure 8A), whereby the C-terminal region dissociates before the N-terminal
region. In contrast, two alanine mutations in the N-terminal region of TC7L2, involving
large truncations of hydrophobic sidechains (I19A and F21A), showed a four-phase dis-
sociation reaction. It is likely that the interface-destabilising mutations in the N-terminal
region cause a partial shift in flux through an alternative dissociation pathway in which
the N-terminal region dissociates before the C-terminal region, resulting in two additional
kinetic phases being observed (Figure 8B). This model is also consistent with the obser-
vation that the alanine mutants in the C-terminal region generally have a greater effect
on the dissociation rate constant than the N-terminal alanine mutants. There are other
potential explanations for the biphasic dissociation kinetics, e.g., heterogenous populations
of the TCF7L2–β-catenin complex. However, such explanations do not readily explain
the consistent site-specific effects of mutations in TCF7L2 (N-terminal versus C-terminal
versus middle region) on kinetics.
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Figure 8. Schematic showing the proposed mechanism of dissociation of TCF7L2–β-catenin complex. TCF7L2 is in red,
and β-catenin in cyan. (A) shows the sequential dissociation pathway in which the C-terminal region of TCF7L2 always
dissociates before the N-terminal region. (B) For destabilising N-terminal mutants, there are two parallel dissociation
pathways in which either the N-terminal region or the C-terminal region dissociates first.
The general trend for IDP interactions is that increasing ionic strength decreases kon
and has a minimal effect on koff [51,65,71–73]. In contrast, for TCF7L2–β-catenin, there is a
roughly equal effect of ionic strength on both dissociation and association—considering
either of the two dissociation phases, Γo f fNaCl is similar in magnitude to Γ
on
NaCl . From the
sum of ΓonNaCl and Γ
o f f
NaCl , we could estimate a value of Γ
Kd, kin
NaCl ≈ −3, which means that the
TCF7L2–β-catenin complex is destabilised by three orders of magnitude for every order
of magnitude increase in ionic strength. This sensitivity is relatively high compared to
other IDP–protein interactions (e.g., ΓKd, kinNaCl ≈ −1 for the ACTR–NCBD interaction [72];
−1.4 > ΓKd, kinNaCl > −2.4 for various HPV E7 constructs binding to Rb [65]). There are parallels
between our findings and those for the ACTR–NCBD interaction [72]. When ionic strength
was increased, a reversal in the overall charge of NCBD occurred from positive to negative.
The explanation given for this effect was that the highly positively charged NCBD attracts
a shell of negatively charge chloride ions. At a higher ionic strength, sufficient chloride
ions are attracted to this shell to completely screen and eventually overwhelm the positive
charge. We believe that a similar behaviour occurs with TCF7L2–β-catenin, with a shell of
positively charged sodium ions forming around the negatively charged variable region of
TC7L2. The decrease in ΓonNaCl upon mutation to the alanine of all five charged residues can
be readily explained, as increasing the ionic strength has less of an effect on the interaction
with β-catenin. The concept of an ionic shell/screen rationalises the unusually high Γo f fNaCl ,
as well as the magnitude of the effect of the 5X Glu-to-Ala mutation on Γo f fNaCl . As the
variable region fluctuates between different conformations, it periodically dissociates from
the surface of β-catenin. When TCF7L2 is separated from β-catenin, the negatively charged
residues can recruit a shell of positively charged sodium ions that inhibit re-association and
promote complete dissociation. This effect increases in magnitude with increasing ionic
strength and is ablated when the five charged residues are mutated to alanine in the 5X
construct. Intriguingly the results of the recent single-molecule study of the E-cadherin–β-
catenin interaction led to a similar suggestion, whereby there is the continuous detachment
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and reattachment of local E-cadherin segments [57]. We share the authors’ conclusion of a
Velcro-like design of many weak contacts on top of a few persistent interactions.
The alternative pathways of binding and unbinding uncovered here for the ARM
repeat protein β-catenin nicely mirror the alternative folding and unfolding pathways pre-
viously observed and predicted by our group and others for tandem-repeat proteins [74–79].
These phenomena reflect the energy landscapes of the repeating architecture, in which
the internal translational symmetry affords multiple paths of similar energies, and, conse-
quently, small perturbations such as conservative mutations are sufficient to shift the flux
through each. Such behaviour contrasts with many globular proteins, which often have
rather complex topologies. In these proteins, there may only be one way to fold the protein,
and therefore even drastic perturbations such as circular permutants can be insufficient to
enable flux through any other routes [80–82]. In the case of binding, the repeat protein–IDP
interface is also strikingly different from most protein–protein interactions studied to date,
where there is no internal symmetry; it is consequently unlikely that there will be more
than one for association/dissociation. In contrast, here, we looked at a relatively long,
extended fragment of TCF7L2 binding to a very long interface comprising 11 repeat motifs.
Consequently, the potential for the multiple sub-regions to sequentially ‘zip up’ and in
different orders dependent on mutation is great. β-catenin is an important therapeutic
target due to its deregulation in many diseases. However, both its long and relatively
flat surface, as well as the overlapping nature of its interfaces with favourable and un-
favourable partner proteins, have made it difficult to inhibit by conventional techniques.
An understanding of the molecular recognition mechanisms and the site-specific dissection
of the complex pathways of dissociation described here, will help us to design drugs to
target the kinetically accessible interfaces of β-catenin (e.g., the surface that interacts with
the C-terminal region of TCF7L2, which dissociates first) and thereby most effectively
inhibit β-catenin’s transcriptional activity.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/biom11060827/s1. Figure S1: ITC analysis of TCF7L2 constructs binding to β-catenin. The
top panels show the heat signal obtained from a series of injections of different TCF7L2 into the
ITC cell containing β-catenin, and the bottom panels show the binding curves calculated using the
one-site fitting model using the Origin software package. (A–C) are TCF7L2 (1–54), “WT,” and the
fluorescein-labelled WT, respectively, binding to β-catenin. Experiments were performed in PBS,
1 mM DTT, at 30 ◦C. Table S1: Dissociation constants of TCF7L2 constructs binding to β-catenin.
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